URGN · UroGen Pharma Ltd.
$43.62
-1.88 (-4.13%)
At close · Aug 28
Going-concern doubt
— cleared Aug 5, 2026
The latest filing states the doubt was alleviated.
“Based on our cash and cash equivalents and marketable securities as of June 30, 2026, together with management's cash flow projections, we believe we have sufficient cash and cash equivalents to fund our operations beyond one year from the issuance of our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.”View the 10-Q filed Aug 5, 2026
Market Cap
$2.13B
Shares
48.88M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$109.79M
+21.4%
FY2025
Net Income
-$153.49M
-21%
FY2025
Gross Margin
88.66%
-1.5pp
FY2025
Operating Margin
-113.73%
-6.7pp
FY2025
Operating Cash Flow
-$162.44M
-67.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $188.73M | $109.79M | $90.4M | $82.71M | $64.36M | $48.04M | $11.8M | $18K | $1.13M | $8.16M | $17.53M | — | |
| $17.28M | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M | $1.01M | — | $1.8M | $600K | $28K | — | |
| $171.46M | $97.34M | $81.52M | $73.35M | $56.7M | $42.89M | $10.79M | $18K | -$675K | $7.56M | $17.5M | — | |
| — | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% | 100% | -59.84% | 92.65% | 99.84% | — | |
| $61.26M | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M | $47.31M | $49.3M | $36.93M | $18.7M | — | — | |
| — | — | — | — | — | — | — | $60.2M | $39.57M | $8.81M | $6.42M | $1.9M | |
| $176.85M | $155.1M | $121.15M | $93.27M | $82.84M | $87.54M | $90.22M | $60.2M | — | — | — | — | |
| $310K | $307K | $329K | $802K | $924K | $831K | $416K | $300K | $400K | $200K | $200K | — | |
| — | — | — | — | — | — | — | $109.5M | $76.51M | $27.51M | — | — | |
| -$66.65M | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M | -$126.74M | -$109.48M | -$77.18M | -$19.95M | $798K | -$12.41M | |
| — | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% | -1074.15% | -608211.11% | -6842.2% | -244.55% | 4.55% | — | |
| -$66.34M | -$124.56M | -$96.45M | -$64.73M | -$78.12M | -$91.46M | -$126.32M | -$109.18M | -$76.78M | -$19.75M | $998K | — | |
| $3.96M | $5.97M | $8.9M | $2.64M | $938K | $365K | $1.99M | $4.62M | — | — | — | — | |
| -$872K | -$670K | -$229K | $838K | $72K | -$153K | — | -$284K | -$124K | $12K | — | — | |
| -$98.11M | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -$109.37M | -$125.11M | -$105.15M | -$75.53M | -$19.98M | -$1.94M | -$12.69M | |
| -$472K | $78K | $2.83M | $3.92M | $1.76M | $1.45M | $3.37M | — | $125K | $19K | — | — | |
| -$97.64M | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M | -$128.48M | -$105.15M | -$75.66M | -$20M | -$1.94M | -$12.69M | |
| — | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | -6707.18% | -245.16% | -11.07% | — | |
| — | — | — | — | — | — | -$128.48M | -$105.15M | -$75.66M | -$20.83M | -$4.41M | -$13.54M | |
| -$97.64M | -$153.53M | -$126.83M | -$102.13M | -$109.87M | -$111.12M | -$128.49M | -$104.87M | -$75.66M | -$20M | — | — | |
| USD/shares | -$1.97 | -$3.19 | -$2.96 | -$3.55 | -$4.81 | -$4.96 | — | — | — | — | — | — |
| shares | — | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 2.31M | 2.3M |
| shares | — | — | — | — | — | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 2.31M | 2.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
11.78×
Peer median 6.26×
EV/EBIT
—
Peer median 16.92×
P/E (TTM)
—
Peer median 17.76×
Peer medians compare against the 254 similar-size Biotechnology companies (of 524 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Jelmyto | $93,989,000 | $90,398,000 | $82,713,000 | $64,357,000 | $48,042,000 | $11,799,000 |
| Zusduri | $15,799,000 | $0 | — | — | — | — |
Key facts
CIK
1668243
CUSIP
M96088105
13F (30d)
167 filings
167 filers
Visit website
Investor relations